Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia

被引:2
|
作者
Demeter, Judit [1 ]
Hamed, Aryan [2 ]
Laszlo, Szerafin [3 ]
Suvajdzic, Nada [4 ]
Aigner, Silke [5 ]
Boerner, Birgit [5 ]
Staiger, Christiane [5 ]
机构
[1] Semmelweis Univ, Med Sch, Dept Hematol, Budapest, Hungary
[2] Petz Aladar Megyei Oktato Korhaz, Belgyogyaszat Hematol Osztaly 2, Gyor, Hungary
[3] Szabolcs Szatmar Bereg Megyei Korhazak & Egyet Ok, Josa Andras Oktatokorhaz, Haematol Osztaly, Nyiregyhaza, Hungary
[4] Clin Ctr Serbia, Clin Haematol, Belgrade, Serbia
[5] Biotest AG, Landsteinerstr 5, Dreieich, Germany
关键词
BT595; chronic immune thrombocytopenia; ITP; phase III trial; pivotal; PURPURA; STANDARDIZATION; MANAGEMENT; CHILDREN;
D O I
10.1111/tme.12943
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose This trial investigated the efficacy and safety of the new 10% human intravenous immunoglobulin (IVIg) BT595 (Yimmugo (R)). Methods Adult patients with chronic immune thrombocytopenia (ITP) received a total dose of 2 g/kg body weight (bw) IVIg either over 2 or 5 days. Results Response as defined by the European Medicines Agency (EMA) was achieved in 18 of 34 patients (52.9%) in the full analysis set (FAS), with a complete response in 11 patients (32.4%). The median time to response was 1.0 days (range 1-4); the median duration was 28.0 days. In a subgroup with a baseline platelet count < 20*10(9)/L evaluated according to FDA criteria, a platelet response >= 50*10(9)/L was achieved in 18 of 19 patients at day 8. No fatal case occured. One serious treatment-emergent adverse event (TEAE) (anaemia, not related) was reported (2.9%). The most frequent infusional adverse drug reaction (ADR) was headache, which was reported for 14.7% of all patients. All other infusional ADRs (pyrexia, [intravascular] haemolysis, skin reaction, tinnitus, and Coombs test positive) occurred in only one patient (2.9%). Premedication was administered only once. The 5-day schedule showed less side effects with similar efficacy. Conclusion The benefit-risk profile of BT595 is favourable.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 50 条
  • [41] A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmuneA®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency
    Krivan, Gergely
    Chernyshova, Ludmila
    Kostyuchenko, Larysa
    Lange, Andrzej
    Nyul, Zoltan
    Derfalvi, Beata
    Musial, Jacek
    Bellon, Anne
    Kappler, Martin
    Sadoun, Alain
    Bernatowska, Ewa
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (06) : 539 - 547
  • [42] Efficacy, Pharmacokinetics and Safety of I10, a Novel 10 % Intravenous Immunoglobulin in Patients with Primary Immune Deficiency (PID): a Prospective Multicentre Study
    Krivan, Gergely
    Chernyshova, Ludmila
    Kostyuchenko, Larysa
    Lange, Andrzej
    Nyul, Zoltan
    Derfalvi, Beata
    Musial, Jacek
    Bellon, Anne
    Kappler, Martin
    Sadoun, Alain
    Bernatowska, Ewa
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S47 - S48
  • [43] A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency
    Gergely Krivan
    Ludmila Chernyshova
    Larysa Kostyuchenko
    Andrzej Lange
    Zoltan Nyul
    Beata Derfalvi
    Jacek Musial
    Anne Bellon
    Martin Kappler
    Alain Sadoun
    Ewa Bernatowska
    Journal of Clinical Immunology, 2017, 37 : 539 - 547
  • [44] Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
    S. Chandrakala
    Manoj Toshniwal
    Mitesh Halvawala
    Namita Padwal
    Neeraj Sidharthan
    Pankaj Malhotra
    B. Prashantha
    Riya Ballikar
    Sandip Shah
    Shashikant Apte
    T. Kasi Viswanathan
    Vijay Ramanan
    Akhilesh Sharma
    Dattatray Pawar
    Roshan Pawar
    Vinayaka Shahavi
    Indian Journal of Hematology and Blood Transfusion, 2023, 39 : 435 - 441
  • [45] Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
    Kuter, David J.
    Bussel, James B.
    Newland, Adrian
    Baker, Ross I.
    Lyons, Roger M.
    Wasser, Jeffrey
    Viallard, Jean-Francois
    Macik, Gail
    Rummel, Mathias
    Nie, Kun
    Jun, Susie
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (03) : 411 - 423
  • [46] The treatment of idiopathic thrombocytopenic purpura in adults: The efficacy of domestic intravenous immunoglobulin in immune thrombocytopenia
    Pugina, SA
    Evdokimova, NM
    Rastorguev, GG
    Samoilova, OS
    Sorokina, IV
    Sidnev, GV
    Vasilyev, DM
    Anastasiev, VV
    Milovidova, OV
    Molodovskaya, EV
    Borovkov, NN
    TERAPEVTICHESKII ARKHIV, 1999, 71 (08) : 50 - 54
  • [47] EFFICACY AND SAFETY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IGPRO10 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
    Sabet, Arman
    Mielke, Orell
    van Schaik, Ivo N.
    Leger, Jean-Marc
    Bril, Vera
    van Gloven, Nan
    Hartung, Hans Peter
    Lewis, Richard A.
    Sobue, Gen
    Lawo, John-Philip
    Durn, Billie L.
    Cornblath, David R.
    De Bleecker, Jan L.
    Sommer, Claudia
    Robberecht, Wim
    Saarela, Mika
    Kamienowski, Jerzy
    Stelmasiak, Zbigniew
    Tackenberg, Bjorn
    Merkies, Ingemar S. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E19 - E19
  • [48] Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
    Richard L. Wasserman
    Joseph A. Church
    Mark Stein
    James Moy
    Martha White
    Steven Strausbaugh
    Harry Schroeder
    Mark Ballow
    James Harris
    Isaac Melamed
    David Elkayam
    William Lumry
    Daniel Suez
    Syed M. Rehman
    Journal of Clinical Immunology, 2012, 32 : 663 - 669
  • [49] Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
    Wasserman, Richard L.
    Church, Joseph A.
    Stein, Mark
    Moy, James
    White, Martha
    Strausbaugh, Steven
    Schroeder, Harry
    Ballow, Mark
    Harris, James
    Melamed, Isaac
    Elkayam, David
    Lumry, William
    Suez, Daniel
    Rehman, Syed M.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (04) : 663 - 669
  • [50] Tolerability and safety of the intravenous immunoglobulin octagam® 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials
    Wietek, Stefan
    Svorc, Daniel
    Debes, Anette
    Svae, Tor-Einar
    HEMATOLOGY, 2018, 23 (04) : 242 - 247